Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

RB, Holmgaard; DA, Schaer; Y, Li; SP, Castaneda; MY, Murphy; X, Xu; I, Inigo; J, Dobkin; JR, Manro; PW, Iversen; D, Surguladze; GE, Hall; RD, Novosiadly; KA, Benhadji; GD, Plowman; M, Kalos; KE, Driscoll

doi:10.1186/s40425-018-0356-4

Public

Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.

Shared by NobleBlocks on Jun 4, 2018 • 12:00 AM UTC

Authors:

Holmgaard RB

Schaer DA

Li Y

Abstract

<h4>Background</h4>TGFβ signaling plays a pleotropic role in tumor biology, promoting tumor proliferation, invasion and metastasis, and escape from immune surveillance. Inhibiting TGFβ's immune suppressive effects has become of particular interest as a way to increase the benefit of cancer immunothe...

Subject

Antitumor efficacy

Checkpoint Inhibitors

Galunisertib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!